Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Out-Licensed OAB Treatment Imidafenacin Launched in South Korea: Kyorin Holdings
July 4, 2013
- Low-Dose Lunabell Approved
July 4, 2013
- Manipulation of BMI Data in Kobayashi Pharmaceutical’s Anti-Obesity Drug Clinical Study Suspected
July 3, 2013
- Sandoz to Ratchet Up Promotions for General Practitioners, Dispensing Pharmacies
July 3, 2013
- Latuda Approved for Major Depressive Episodes Associated with Bipolar I Disorder in the US: DSP
July 3, 2013
- Japanese Society of Chemotherapy Joins Hands with Pharmas, Govt to Spur New Antibiotic Development
July 2, 2013
- DSP Adopts Tokyo-Osaka Two Head Office System
July 2, 2013
- Takeda Withdraws European MAA for Anemia Treatment Peginesatide Following Voluntary Recall in US
July 2, 2013
- Gout, Hyperuricemia Treatment Topiloric/Uriadec Tablets Approved: Fuji Yakuhin, Sanwa Kagaku
July 2, 2013
- Astellas’ US Affiliate Agensys to Codevelop ADC with Seattle Genetics
July 1, 2013
- Kyowa Kirin Files NDA for Sustained-Duration G-CSF KRN125, PEGylated Form of Gran
July 1, 2013
- Takeda President Executive Pay Reaches 300 Million Yen, Three Execs Receive Over 700 Million Yen
June 28, 2013
- Novartis Files Combination Drug for Parkinson’s Disease in Japan
June 28, 2013
- Bayer Yakuhin to Shift Resources to Innovative New Drugs: President Brunn
June 28, 2013
- Reasons for Doctors’ Reluctance to Generic Name Prescribing is Time and Effort: CareNet Survey
June 28, 2013
- Tsumura Reports Record Profits through Intensified MR Activities to Educate Doctors about Kampo Medicine
June 28, 2013
- Astellas Begins Global PIII Study of Cytomegalovirus Vaccine
June 27, 2013
- Shionogi Establishes New Chinese Subsidiary
June 27, 2013
- Astellas, Cytokinetics Agree to Develop, Commercialize Skeletal Muscle Activators
June 27, 2013
- Takeda Files BLA for CD, UC Treatment in US
June 27, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…